{"title": "PDF", "author": "PDF", "url": "https://www.adventisthealth.org/documents/glendale/AHGL_OpenClinicalTrials.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "to Evaluate the Safety, Tolerability, and Efficacy of DM199 for the Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) Protocol Number: DM199-2021-0012CerapedicsNCT03438747An Assessment of Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-14PREMIANCT03012776A Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPSTM System 5ImmunityBioNCT03520686A Phase 2, Open-Label, Randomize Stuy of ALT-803, A Fusion Protein Activator of Natural Killer and T Cells, in Combination with Pembrolizumab vs Pmbrolizumab Alone as First-Line Treatment for Patient with Metastatic Non-Small Cell Lung Cancer (NSCLC)6DoterraNCT05218044Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ7GenentechNCT04873362A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy8GenentechNCT03785678A PHASE III, PROSPECTIVE, DOUBLE-BLIND RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF THROMBOLYSIS IN IMAGING-ELIGIBLE, LATE-WINDOW PATIENTS TO ASSESS THE EFFICACY AND SAFETY OF TENECTEPLASE (TIMELESS)9PfizerNCT04821622TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE METASTATIC CASTRATION-SENSITIVE Prostate Cancer TALAPRO211RADIUSNCT03778931Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients with ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor (EMERALD)12PROTECT IVNCT04763200Impella\u00ae-Supported PCI in High-Risk Patients with Complex Coronary Artery Disease and Reduced Left Ventricular Function: The PROTECT IV Trial13Caris Life SciencesTBDDINOSAur: Discovering novel cancer treatment options using a comprehensive NGS-based molecular testing panel in the community setting14ABIOMED ECP NCT05334784Use of the Impella ECP in Patients Undergoing an Elective or Urgent High-Risk Percutaneous Coronary Intervention15AHGL Office of Randomized, Double-blind, Double-dummy, Parallel-group the Efficacy Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib17JanssenTBD\"A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack LIBREXIA-STROKE\"18Dilon Technologies NCT05377229MarginProbe 219Pfizer 1002TBDA randomized, PROTAC) plus palbociclib versus AROMATASE INHIBITOR plus palbociclib for the treatment of Patients with Estrogen Receptor Positive, HER2 Negative breast cancer who have not received any prior systemic anticancer treatment for advanced disease.1PAREXEL Phase I UnitNAServices provided to outside research company2CNSNAServices provided to outside research company3New School ResearchNAServices provided to tolerability, pharmacokinetics, anti-tumor activity of TPX-0022, a novel MET/CSF1R/SRC inhibitor, in patients with advanced solid tumors harboring genetic alterations in MET (SHIELD-1)2TP Therapeutics--RET mutationNCT04161391A Phase 1/2 Study of TPX-0046, a Novel Oral RET/SRC Inhibitor in Adult Subjects With Advanced/Metastatic Solid Tumors Harboring Oncogenic RET Fusions or Mutations3PfizerTBDMulticenter, Randomized, Investigator's Endocrine Treatment Choice \u00b1 GnRH analogue in Patients with Estrogen Receptor Positive, HER-2Negative Advanced Breast Cancer Whose Disease Progressed After One Prior CDK4/6 inhibitor plus Endocrine based Treatment for Advanced disease.4NovartisTBDOciperlimab combo with tislelizumab vs pembrolizumab plus chemo--1st line NSCLC5Cerner Learning Health NetworkTBDFreenome Diagnostic Blood Tests for Cancer Screening6UCLA Stroke NetworkTBDCLARITY study for prevention of secondary stroke7HologicTBDMulti-Center Prospective Non-Randomized Two-Arm Clinical Trial Evaluating Cryoablation for the Treatment of Stage 1 Invasive Breast Cancer in Lieu of Surgical Resection8xCures Vaccine studyNA--Expanded Access Study\"Expanded access to neoantigen synthetic long peptide vaccine in an indivicual patient with advanced malignancy\"9Stemline TherapeuticsNCT05563220Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacastrant in Various Combination In Patients with Metastatic Breast Cancer (ELEVATE)OPEN CLINICAL TRIALS PIPELINE "}